COVID Vaccine Study Previously Blocked by CDC Published, Revealing Key Findings

A significant study on COVID-19 vaccines that faced blockage by the acting director of the Centers for Disease Control and Prevention (CDC) has finally been published in a scientific journal. This research, which previously was set to appear in the CDC’s *Morbidity and Mortality Weekly Report*, has garnered attention for its conclusions regarding the effectiveness of the COVID-19 vaccine in reducing hospitalizations and severe illness among older adults.

Published in *JAMA Network Open*, the study highlights that COVID-19 vaccines effectively cut the risk of hospitalization and severe illness by approximately 50% among adults. The findings come after months of scrutiny surrounding the study’s delayed release, which the Washington Post first reported in April. The acting CDC Director, Jay Bhattacharya, raised concerns about the study’s methodology after it had already passed through a scientific review and received editorial approval.

The controversy surrounding this research has focused more on the methodology rather than the vaccine’s protective effects. Experts maintain that the reasons for blocking the study were unfounded. Dr. Robert Glatter, an emergency physician, emphasized that legitimate concerns about research should be addressed through the standard scientific process, not through suppression. He stated that halting accepted research without a transparent scientific rationale goes against regulatory norms.

The newly published study analyzed data from patients seeking care for COVID-19-like symptoms across seven states. It found that adults who received the updated 2025-2026 COVID-19 vaccine had significantly lower chances of requiring emergency or inpatient care compared to those who had not been vaccinated with that season’s formula. The research also aimed to assess the benefits of seasonal COVID-19 vaccines for individuals with prior vaccinations or infections.

Dr. William Schaffner, a preventive medicine and infectious diseases expert, reinforced the study’s message that, despite COVID-19 still posing a risk, vaccinations offer considerable protection against severe illness and hospitalization. He noted that even individuals with past infections or vaccinations benefit from receiving the current vaccine.

The study utilized data from the CDC-funded VISION Network, which connects electronic health records and vaccination records. It included adults aged 18 and older who sought medical care between September and December 2025. The findings indicated that the updated vaccine reduced the risk of emergency department visits by 50% and hospitalization by 55%. Among older adults, the vaccine demonstrated a 48% effectiveness against emergency visits and a 53% effectiveness against hospitalization.

The recent publication has reignited discussions about the standards for evaluating vaccine effectiveness. Bhattacharya has voiced his preference for longitudinal cohort studies over the test-negative design used in this research, arguing that they provide stronger evidence for vaccine evaluation.

In light of the study’s findings, public health officials urge ongoing vaccination as a critical measure in managing COVID-19, particularly for those who have previously been infected or vaccinated. This situation underscores the importance of transparent dialogue and research in building public confidence in vaccines, especially in the face of ongoing debates over vaccine safety and effectiveness.